4//SEC Filing
Clague Laura 4
Accession 0001209191-22-003046
CIK 0001438533other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 4:05 PM ET
Size
7.2 KB
Accession
0001209191-22-003046
Insider Transaction Report
Form 4
Clague Laura
Chief Financial Officer
Transactions
- Award
Common Stock
2022-01-10+7,500→ 38,816 total - Sale
Common Stock
2022-01-11$27.40/sh−7,500$205,500→ 31,316 total
Footnotes (2)
- [F1]On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
- [F2]The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001388773
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 4:05 PM ET
- Size
- 7.2 KB